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Abstract
Purpose The prognostic significance of lactate dehydrogenase (LDH) in patients with metastatic seminoma is not defined. 
We investigated the prognostic impact of LDH levels prior to first-line systemic treatment and other clinical characteristics 
in this subset of patients.
Methods Files from two registry studies and one single-institution database were analyzed retrospectively. Uni- and mul-
tivariate analyses were conducted to identify patient characteristics associated with recurrence free survival (RFS), overall 
survival (OS), and complete response rate (CRR).
Results The dataset included 351 metastatic seminoma patients with a median follow-up of 5.36 years. Five-year RFS, OS 
and CRR were 82%, 89% and 52%, respectively. Explorative analysis revealed a cut-off LDH level of < 2.5 upper limit of 
normal (ULN) (n = 228) vs. ≥ 2.5 ULN (n = 123) to be associated with a significant difference concerning OS associated 
with 5-years OS rates of 93% vs. 83% (p = 0.001) which was confirmed in multivariate analysis (HR 2.87; p = 0.004). Fur-
thermore, the cut-off LDH < 2.5 ULN vs. ≥ 2.5 ULN correlated with RFS and CRR associated with a 5-years RFS rate and 
CRR of 76% vs. 86% (p = 0.012) and 32% vs. 59% (p  ≤  0.001), respectively.
Conclusions LDH levels correlate with treatment response and survival in metastatic seminoma patients and should be 
considered for their prognostic stratification.
Keywords Seminoma · Lactate dehydrogenase · Prognostic markers · Upper limit of normal
Introduction
Germ cell tumors (GCTs) are the most common solid malig-
nancy in young men aged between 15 and 35 years [1]. 
Metastatic GCTs with both seminomatous and non-semino-
matous histology are extremely sensitive to cisplatin-based 
chemotherapy as part of a multimodal treatment approach 
associated with 5-years overall survival (OS) rates from 50% 
to 90% depending on the risk group [2, 3]. The serum tumor 
markers beta subunit of human chorionic gonadotropin 
(HCG) and alpha-fetoprotein (AFP) are used for diagnosis, 
monitoring of treatment efficacy, and follow-up procedures 
[4]. In patients with non-seminomatous GCTs, the serum 
tumor markers HCG, AFP and LDH (lactate dehydroge-
nase) are used for the prognostic stratification according 
to the International Germ Cell Cancer Cooperation Group 
(IGCCCG) classification; however, tumor markers are not 
considered for further prognostic estimations of seminoma 
patients. Only approximately 30% of seminoma patients 
with advanced disease have serum HCG levels above nor-
mal [5–7], and unequivocally increased AFP levels are not 
consistent with pure seminomatous histology. In the previ-
ous work of our group, we analyzed a cohort of seminoma 
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patients with elevated HCG levels and demonstrated that 
HCG levels are not associated with the outcome except in a 
small subset of advanced-stage patients with excessive HCG 
marker increases detected pre-orchiectomy [8]. Although 
pre-orchiectomy tumor markers are principally not consid-
ered for the prognostic stratification of GCT patients [9, 10] 
the results of our study revealed that HCG is not sufficient as 
a prognostic marker for seminoma patients [11]. Already in 
1981, elevated LDH serum levels were reported to correlate 
with tumor bulk and impaired survival times in a small series 
of GCT patients [12], while other studies revealed a correla-
tion between LDH serum levels and disease burden in GCT 
patients [7, 13]. The prognostic significance of LDH levels 
in patients with pure seminomatous histology, however, was 
never yet defined. This study examines the prognostic impact 
of LDH levels detected prior to first-line systemic treatment 
concerning recurrence-free survival (RFS), overall survival 
(OS), and complete response rate (CRR) after forming an 
extended group of seminoma patients with advanced disease.
Patients and methods
Study population and inclusion criteria
We analyzed a contemporary cohort of seminoma patients 
who had been treated from 1983 to 2017. The patients 
were retrospectively identified in 20 GCT expert centers or 
study groups across Europe, the Russian Federation, and 
Australia that participated in two previous registry studies 
on behalf of the global germ cell collaborative group (G3) 
with additional data from one single institution analysis. 
Previous registry studies provided data for the analysis 
of intermediate prognosis patients in metastatic GCT and 
for HCG positive seminoma patients, respectively [8, 14]. 
Registry studies were approved by the Ethics Commit-
tee of the Medical Association, Hamburg, Germany (Ref. 
No.: PV5432 and PV5050). Monocentric data acquisition 
was in line with local requirements according to Hamburg 
Hospital Act (HmbKHG)§ 12 HmbKHG. Patients were 
eligible for inclusion if they had (1) confirmed pure semi-
nomatous histology according to histological examination 
by local pathologists, (2) advanced disease including the 
clinical stages IIA-C and IIIA-C according to Union for 
International Cancer Control (UICC) [15], (3) systemic 
treatment (4) availability of LDH levels detected prior 
to first-line systemic treatment (i.e. post-orchiectomy if 
carried out). Patients were excluded due to the follow-
ing reasons: (1) non-seminomatous histology, (2) local-
ized disease or (3) absence of LDH levels prior to first 
line treatment (4) treatment with radiotherapy only. LDH 
levels prior to first-line systemic treatment were deter-
mined in institutional laboratories according to interna-
tional practice guidelines [16]. Due to variable measure-
ment techniques applied in the participating institution 
with differences concerning reference ranges, we chose to 
analyze individual measurements as x-fold values of the 
upper limit of normal (ULN) according to local laboratory 
measurement technologies.
Outcome measurements and endpoint
Our study hypothesis was that elevated LDH levels 
detected prior to first-line tretament inversely correlate 
with outcome in seminoma patients with metastatic dis-
ease. End-points of the study were, RFS defined as the 
time from the end of first line treatment to the date of dis-
ease recurrence, OS defined as the time from the first diag-
nosis until death from any cause or last date of follow-up, 
and complete response rate (CRR) defined as the rate of 
complete remission achieved during first-line chemother-
apy. Complete remission was defined as no radiological 
evidence of residual disease and normalized tumor mark-
ers after completion of systemic treatment or radiotherapy. 
Patients lost to follow-up were censored at the date of their 
last visit.
Statistical analysis
To explore a correlation between rising LDH levels and out-
come patients were stratified according to the extent of their 
LDH levels detected prior to first-line treatment using the 
following model: (1) < 1.5 ULN vs. (2) 1.5 ULN to 2 ULN 
(3) vs. > 2–3 ULN, (4) vs. > 3.0 ULN. To find a cut-off level 
which reveals the highest difference between beneficial and 
impaired outcomes, the following cut-off levels were tested: 
LDH prior to first-line treatment ≥ 1.5 ULN vs. < 1.5 ULN; 
LDH prior to first-line treatment ≥ 2.0 ULN vs. < 2.0 ULN; 
LDH prior to first-line treatment ≥ 2.5 ULN vs. < 2.5 ULN; 
LDH prior to first-line treatment ≥ 3.0 ULN vs. < 3.0 ULN. 
Other potential prognostic indicators considered for statisti-
cal analysis were age, IGCCCG risk category, primary tes-
ticular vs. extragonadal, pulmonary vs. other visceral metas-
tases, and HCG levels prior to first-line treatment (≥ 2.000 
IU/l vs. < 2.000 IU/l and ≥ 5.000 IU/l vs. < 5.000 IU/l). 
Survival analysis was conducted using the Kaplan–Meier 
method [17]. A log-rank test was applied to compare sur-
vival rates. Patient characteristics found to be associated 
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with outcome (p < 0.1) were tested in a multivariate Cox 
regression model. Variables were found to be significant if 
a two-sided p value was < 0.05. To analyze the correlation 
between patient characteristics and CRR Pearson Chi-square 
test was conducted. Statistical analysis was performed using 
Statistical Package for the Social Sciences (SPSS, version 
17.0; IBM Corp, Armonk, NY, USA).
Results
Patient characteristics
Data files from two registry studies and one single institu-
tion database were screened. Of 1183 files 351 seminoma 
patients with metastatic disease were considered eligible 
for analysis (Fig. 1). Clinical characteristics of the patient 
cohort are described in Table 1. The median follow-up 
time since diagnosis was 5.36 years (interquartile range: 
6.32). The cohort included patients with clinical stages 
IIA-C (n = 209) and IIIA-C (n = 129) according to UICC 
[14]. In 13 cases the exact stage of advanced disease 
remained undefined. LDH levels upper limit of normal 
prior to first-line treatment according to local laboratory 
findings were detected in 261 of 351 (74%).
Treatment and response
Systemic cisplatin-based chemotherapy according to 
institutional standards was administered in 274 patients 
(78%). Altogether 60 systemic chemotherapy regimens 
were defined as ‘others’ (17%) while in 13 cases further 
information on treatment regimens was absent (4%). Addi-
tional surgery after systemic treatment was documented 
in 21 patients (6%). Treatment response data were avail-
able in 274 patients. Complete remissions were achieved 
in 145 (53%), partial remissions in 108 (39%), stable 
disease in 11 (4%), and progressive disease in 10 (4%) 
patients. Details of the treatment regimens are summarized 
in Table 1.
Correlation of patient characteristics with overall 
survival (OS) and recurrence‑free survival (RFS)
The 5-year OS rate of the total cohort was 89%. The strati-
fication of patients according to their LDH levels detected 
prior to first-line treatment suggests an inverse correlation 
between rising LDH levels and outcome. Five year OS rates 
of 94% were detected for patients with LDH levels < 1.5 
ULN (n = 155); 87% for patients with LDH levels from 1.5 
ULN to 2 ULN (n = 54), 76% for patients with LDH levels 
from > 2 to 3 ULN (n = 35) and 86% for patients with LDH 
levels > 3.0 ULN (n = 107) (p = 0.003) (Fig. 2). To evaluate 
a cut-off providing the highest discrepancy between patients 
with good and impaired outcomes, patients were consecu-
tively categorized according to their extent of LDH levels. 
Cut-off levels tested are described in “Outcome measure-
ments and endpoint”. Regarding this stratification, our analy-
sis revealed the cut-off level of LDH ≥ 2.5 ULN prior to first-
line treatment (n = 123) vs. < 2.5 ULN (n = 228) providing 
the highest difference concerning outcome associated with a 
5-year OS rate of 83% vs. 93% (p = 0.001) (Table 2; Fig. 2). 
Other factors correlating with an impaired OS rate were 
Fig. 1  Overview of the patient 
cohort: total cohort divided into 
a number of patients in different 
analyses G3 HCG posive seminoma 
registry 
Total number of paents: 427 
G3 Intermediate prognosis 
registry  
Total number of paents: 681
Monocentric analysis 
Total number of paents: 75 
Eligible for analysis: 316 
Reason for exclusion: 
no LDH value prior first 
line available
Radiaon therapy only
Eligible for analysis: 22 
Reason for exclusion: 
Paents with non-
seminoma 
Eligible for analysis: 13 
Reason for exclusion: 
No LDH value prior 
first line and paents 
with non-seminoma
Radiaon therapy only
Total cohort: 351 paents 
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HCG levels ≥ 2.000 IU/l vs. < 2.000 IU/l (n = 12) detected 
prior to first-line treatment associated with a 5-year OS 
rate of 82% vs. 89% (p = 0.022) and age above the median 
revealed an impaired 5-year survival rate of 86% vs. 91% vs. 
(p = 0.024). Multivariate analysis confirmed LDH ≥ 2.5 ULN 
as the only independent prognostic factor concerning OS 
(HR 2.86; 95% CI 1.41–5.85; p = 0.004). Results of the out-
come analysis are illustrated in detail in Table 2. Concerning 
the RFS, LDH cut-off levels and other patient characteristics 
were tested as well. The 5-year RFS rate was 83%. Univari-
ate analysis revealed LDH levels prior to first-line treatment 
as the only variable to be associated with the RFS. Here 
LDH levels ≥ 2.5 ULN vs. < 2.5 ULN were associated with 
a five-year RFS rate of 76% vs. 86% (p = 0.012) (Table 2; 
Fig. 2). As no other variable was detected to be significant, 
further multivariate analysis was not conducted.
Correlation of patient characteristics with complete 
remission rate
The complete remission rate was 53%. Chi-square test 
revealed LDH levels prior to first-line treatment to inversely 
correlate with CRR. Here LDH levels ≥ 2.5 ULN vs. < 2.5 
ULN were associated with a CRR of 32% compared to 59% 
(p < 0.001), respectively. None of the other clinical charac-
teristics significantly correlated with CRR (Table 2).
Discussion
This registry study proved a significant correlation of 
serum LDH levels with OS, RFS and CRR in patients with 
metastasized seminoma. Elevated LDH levels were already 
associated with poorer outcomes including several solid 
Table 1  Patient characteristics
UICC Union for International Cancer Control, BEP Bleomycin, Etoposide, Cisplatin, VIP Vindensine, Ifosfamide, Cisplatin, PE Cisplatin 
Etoposide, SAKK Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
Characteristics Absolute number of patients n = 351 100%
LDH values prior to first-line treatment (ULN)
  < 1.5 155 44%
  > 1.5–2 54 15%
  > 2–3 35 10%
  > 3 107 30%
Median age in years 39.9 (Range 18–79)





 Good prognosis 276 78%
 Intermediate prognosis 65 19%
 Missing 10 3%
Stage UICC
 UICC Stage II 209 59%
 UICC Stage III 129 37%
 Missing 13 4%
Treatment regimens
 Three cycles of BEP 126 36%
 Four cycles of BEP 122 35%
 Three to four cycles VIP 8 2%
 Four cycles of PE 18 5%
 Four cycles of CE 4 1%
 Defined as “others” 60 17%
 Missing 13 4%
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tumor and hematologic malignancies [18–22] but the value 
of LDH as a prognostic marker for seminoma patients 
remained unclear. To find new categories that significantly 
correlate with outcome, our analysis investigates LDH lev-
els and other patient characteristics as potential prognos-
tic markers, hypothesizing that LDH inversely correlates 
with outcome in seminoma patients as well. We herein 
found a negative correlation between rising LDH levels 
and outcome concerning OS in consideration of uni- and 
multivariate analyses. According to different LDH thresh-
olds, the cut-off level of ≥ 2.5 ULN vs. < 2.5 ULN pro-
vided a high discrepancy between patients with impaired 
and beneficial outcomes. Of note, this cut-off was also 
significantly relevant concerning RFS and CRR within our 
analysis and is in line with results recently reported by the 
EORTC IGCCCG-update consortium [23].
This analysis can add substantially new information to the 
field of testis cancer by identifying LDH levels > 2.5 ULN 
as a novel marker to define seminoma patients at high risk.
Limitations of the study are a retrospective design and 
partially incomplete datasets. Another limitation is that the 
majority of patients were identified from an earlier registry 
study including exclusively seminoma patients with HCG 
levels above normal reference ranges. As our previous study 
demonstrated that HCG levels are not associated with the 
outcome except in a small subset of advanced-stage patients 
with excessive HCG marker increases detected pre-orchiec-
tomy we think that this large subset of marker positive HCG 
levels in our cohort will not interfere with data of seminoma 
patients without any elevated HCG levels. We therefore con-
sider the value of elevated LDH levels to identify seminoma 
patients with an inferior prognosis as promising new infor-
mation, representing an easily applicable assessment for the 
daily clinical routine. Here strategies for treatment escalation 
or de-escalation based on LDH might be worth to be consid-
ered for future projects.
Conclusions
This retrospective series of advanced seminoma patients 
highlights the prognostic impact of LDH levels detected 
prior to first-line systemic treatment concerning OS, RFS 
and CRR.
LDH levels expound a distinct utility to characterize a 
subgroup of seminoma patients with an inferior outcome.
Additional research to further evaluate the potential util-
ity of this marker for prognostic stratification and treatment 
adjustments is needed.
Fig. 2  Patients were stratified into four cohorts according to increas-
ing LDH levels detected prior to first-line treatment:  <  1.5 upper 
limit of normal (ULN); 1.5–2; from >  2 to 3, and >  3 ULN. The 
graph demonstrates a correlation between rising LDH levels and 
impaired outcome concerning OS (a). Stratification of patients 
according to prior to first-line treatment LDH levels identifies ≥ 2.5 
ULN as a cut-off level with significant prognostic impact concerning 
OS (b) and RFS (c)
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Table 2  Results of univariate and multivariate analyses of OS, RFS and CRR 
LDH lactate dehydrogenase, IGCCCG International Germ Cell Cancer Collaborative Group
Factor Difference 5-year OS rate Log-rank test
p value
LDH prior to first-line < 1.5 ULN vs. ≥ 1.5 ULN 85% vs. 94% 0.021
LDH prior to first-line ≥ 2.5 ULN vs. < 2.0 ULN 84% vs. 94% 0.003
LDH prior to first-line ≥ 2.5 ULN vs. < 2.5 ULN 83% vs. 93% 0.001
LDH prior to first-line ≥ 3.0 ULN vs. < 3.0 ULN 87% vs. 91% 0.054
Age above vs. below median 86% vs. 91% 0.024
IGCCCG good vs. intermediate 88% vs. 90% 0.240
HCG prior to first line > 2000 U/l 82% vs. 89% 0.022
HCG prior to first line > 5000 U/l 87% vs. 89% 0.063
Factor HR 95% CI p value
LDH prior to first-line ≥ 2.5 ULN vs. < 2.5 ULN 2.87 1.41–5.85 0.004
HCG prior to first-line > 2000 U/l 0.41 0.14–1.19 0.102
Age above vs. below median 1.67 0.86–3.25 0.132
Factor Difference 5-year RFS rate Log-rank 
test p 
value
LDH prior to first-line ≥ 1.5 ULN vs. < 1.5 ULN 79% vs. 89% 0.027
LDH prior to first-line ≥ 2.0 ULN vs. < 2.0 ULN 78% vs. 86% 0.082
LDH prior to first-line ≥ 2.5 ULN vs. < 2.5 ULN 76% vs. 86% 0.012
LDH prior to first-line ≥ 3.0 ULN vs. < 3.0 ULN 78% vs. 86% 0.087
Age above vs. below median 81% vs. 83% 0.673
IGCCCG good vs. intermediate 82% vs. 84% 0.933
HCG prior to first-line > 2000 U/l 73% vs. 84% 0.552
HCG prior to first-line > 5000 U/l 72% vs. 82% 0.063
Factor Difference CRR Chi-square test
p value
LDH prior to first-line ≥ 1.5 ULN vs. < 1.5 ULN 39% vs. 64% 0.005
LDH prior to first-line ≥ 2.0 ULN vs. < 2.0 ULN 48% vs.50%  < 0.001
LDH prior to first-line ≥ 2.5 ULN vs. < 2.5 ULN 32% vs. 59%  < 0.001
LDH prior to first-line ≥ 3.0 ULN vs. < 3.0 ULN 21% vs. 78%  < 0.001
Age ≥ median vs. < median 49% vs. 52% 0.655
Gonadal vs. extragonadal 78% vs.22% 0.480
IGCCCG good vs. intermediate 46% vs. 54% 0.382
HCG prior to first-line < vs. > 2000 U/l 53% vs. 57% 0.821
HCG prior to first-line < vs. > 5000 U/l 52% vs. 80% 0.221
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